Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Treatment of Heart Failure: a Non-interventional Observational Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF - GREECE)

NCT05635331 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05635331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05635331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Treatment of Heart Failure: a Non-interventional Observational Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF - GREECE)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 28, 2022
Completion date
December 3, 2024
Enrollment
257 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure